Table 2.

Adverse events by dose groups (number of subjects with an AE) by preferred term.

			GNbAC1
System Organ Class##Preferred Term	Placebo##(n=6)	6 mg/kg## (n=5)	18 mg/kg## (n=5)	36 mg/kg## (n=5)
General Disorders And Administration Site Conditions	0	0	0	1
Influenza-Like Illness	0	0	0	1
Infections And Infestations	0	0	2	1
Nasopharyngitis	0	0	1	0
Rhinitis	0	0	0	1
Upper Respiratory Tract Infection	0	0	1	0
Injury, Poisoning And Procedural Complications	0	1	0	0
Post Lumbar Puncture Syndrome	0	1	0	0
Investigations	0	0	0	1
Alanine Aminotransferase Increased	0	0	0	1
Musculoskeletal And Connective Tissue Disorders	1	1	1	1
Back Pain	1	0	1	0
Joint Effusion	0	1	0	0
Musculoskeletal Pain	0	0	0	1
Myalgia	0	0	0	1
Nervous System Disorders	1	0	0	1
Dizziness Postural	0	0	0	1
Headache	1	0	0	0